Clearside Biomedical, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 9.28 million compared to USD 7.64 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.13 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | +3.12% | +3.94% | +12.82% |
05-13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
05-09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.82% | 95.66M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023